Lazertinib, as a targeted drug for EGFR mutant non-small cell lung cancer, has clear restrictions on its use, including contraindications for special populations, dosage adjustment requirements, and adverse reaction management standards. The following provides a detailed explanation of its restrictive requirements from a clinical application perspective.

1. Special population restrictions

(1) Pregnancy period: May cause harm to the fetus, pregnancy status should be confirmed and prohibited before treatment.

(2) Breastfeeding period: Lack of milk excretion data, breastfeeding is prohibited during treatment and within 3 weeks after the last dose.

(3) Reproductive population: Women need to take contraceptive measures during treatment and 3 weeks after discontinuing medication; Men should provide equal protection to their female partners.

(4) Children: Safety and effectiveness have not been established, use is prohibited.

2 Organ Function Limitations

(1) Liver function: Mild/moderate damage does not require dose adjustment; Severe damage lacks data and should be used with caution.

(2) Renal function: Mild/moderate damage does not require adjustment; Severe damage should be reduced to 75mg once daily.

3 dose adjustment restrictions

(1) The initial dose is 240mg/day, which is gradually reduced to 80mg/day in three stages according to the degree of adverse reactions, and ultimately needs to be discontinued.

(2) Interstitial lung disease requires permanent discontinuation of medication, and venous thrombosis requires anticoagulant therapy.

4 Medication Management Restrictions

(1) Genetic testing is required to confirm EGFR sensitive mutations before use.

(2) The incidence of eye toxicity is 16%, and regular eye examinations are required.

(3) 86% of patients will experience skin reactions, and grade 3 rash requires dosage adjustment.

5 Prevention and Management Measures

(1) Anticoagulation prevention: Prophylactic anticoagulation is required 4 months before treatment, and vitamin K antagonists are contraindicated.

(2) Skin care: Use non-alcoholic moisturizer, wear sunscreen and limit sun exposure.

(3) Monitoring requirements: Regularly check blood pressure, blood glucose, and liver function indicators, and seek medical attention promptly in case of abnormalities.